Skip to main content
OpenTrials
Completed

NCT Number: NCT01527500

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study, and not due to any safety issues or concerns. Cohort 2 is not referred to again and part B cohort 1 is referred to as part B alone in the remainder of the document and is the subject of this report.

Part B was conducted to assess the safety and tolerability of a single intravitreal (IVT) LFG316 10 mg/100 µL injection. There was no efficacy evaluation in Part B. The study employed a multicenter, randomized, sham - controlled, single masked design. Eight patients with advanced AMD were planned to be randomized in a 3:1 ratio to receive a single IVT dose of LFG316 (10 mg/100 µL) or sham injection. Patients assigned to a sham injection were treated the same as those assigned to LFG316, except that the hub of an empty syringe (without needle) was placed against the eye instead of the IVT injection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Geographic Atrophy Age-Related Macular Degeneration Blindness Eye Diseases Macular Degeneration Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Retinal Degeneration Retinal Diseases Sensation Disorders Signs and Symptoms Vision Disorders

Age range

55 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Novartis Investigative Site, Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of AMD if enrolled in Part B of study
  • Geographic atrophy in at least one eye if enrolled in Part A of study
  • ETDRS best corrected visual acuity of 60 letters or worse (~≤ 20/63)

Exclusion criteria

  • Retinal disease other than AMD
  • History of choroidal neovascularization
  • Severe cataract
  • History of infectious uveitis or endophthalmitis
  • Eye surgery in the non-study eye within 30 days prior to study
  • Eye surgery or IVT injection in the study eye within 90 days prior to study
  • Other protocol-defined inclusion/exclusion criteria may apply

Treatment and study plan

LFG316

Drug

LFG316 5 mg/50 μL solution for IVT injection,

sham

Drug

Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)

LFG316 Lower dose

Drug

LFG316 5 mg/50 μL solution for IVT Injection

Primary outcomes

  1. Part A: Geographic Atrophy (GA) Lesion Growth Measured by Fundus Autofluorescence (FAF) From Baseline to Day 505

    Time frame: Day 1 to Day 505 (starting from the day of first intravitreal injection until Day 505)

    Geographic atrophy (GA) lesion growth measured by fundus autofluorescence (FAF) from baseline to Day 505.

  2. Part A: Sensitivity Analysis of the Primary End Point: Mixed Effects Model for Repeated Measurements on GA Lesion Growth Measured by Fundus Autoflourescence

    Time frame: The primary objective was from Day 1 to Day 337, however data was captured to Day 505 as exploratory objective

    Number is the Estimated Difference (95% CI) in lesion size.

  3. Part B: Safety and Tolerability of a Single Intravitreal (IVT) Dose of 10 mg/100 μL of LFG316 in Patients With Advanced AMD).

    Time frame: Day 1 to Day 85

    This primary outcome (for Part B) is reported under the Adverse Events section.

Secondary outcomes

  1. Part A: Change From Baseline in GA Lesions Growth Measured by Fundus Autofluorescence

    Time frame: Day 1 to Day 169 and Day 505 (starting from the day of first intravitreal injection until Day 505)

    Mean change in GA lesion growth from baseline to Day 169 and Day 505.

  2. Part A: Change in Best Corrected Visual Acuity (BCVA) as Measured by the EDTRS (Early Treatment of Diabetic Retinopathy Study) Scale From Baseline to Days 169, 337 & 505 in Patients Receiving Every 28 Days, Successive IVT Doses of LFG316 Compared to Sham

    Time frame: Baseline Day 1, Day 169, Day 337 to Day 505

    Part A: Summary of best corrected visual acuity over time, statistical analysis of change in best corrected visual acuity over time Parameter: Visual Acuity (EDTRS letter) BCVA scale is 0-100, worst is 0 and best 100 Eye: STUDY

  3. Part A: Summary of Best Corrected Visual Acuity Over Time, Statistical Analysis of Change in Best Corrected Visual Acuity Over Time Parameter: Visual Acuity (EDTRS Letter) BCVA Scale is 0-100, Worst is 0 and Best 100 Eye: FELLOW

    Time frame: Baseline Day 1, Day 169, Day 337 to Day 505

    Part A: Summary of best corrected visual acuity over time, statistical analysis of change in best corrected visual acuity over time Parameter: Visual Acuity (EDTRS letter) BCVA scale is 0-100, worst is 0 and best 100 Eye: FELLOW

  4. Part A: Concentrations of Total LFG316 in Blood During the Course of the Study

    Time frame: Day 1 to Day 559 (starting from the day of first intravitreal injection to day 559)

    Summary statistic of total LFG316 concentrations (pharmacokinetic analysis set)

    n=number of participants, h=hours after the last administered dose e.g.; 0.0 means just before dosing. If the mean concentration is 0.00, that means there is no drug in the bloodstream

  5. Part A: Concentrations of Total C5 in Blood During the Course of the Study

    Time frame: Day 1 to Day 559 (starting from the day of first intravitreal injection to day 559)

    Summary statistic of total C5 concentrations n=number of participants, h=scheduled sampling time

  6. Part B: AUC (Area Under the Curve) - Summary Statistics for PK Parameters

    Time frame: Day 1 to Day 85 (starting from the day of first intravitreal injection to day 85)

    Summary statistic of total LFG316 concentrations (pharmacokinetic analysis set)

    n=number of participants, h=scheduled sampling time

  7. Tmax (hr)

    Time frame: Day 1 to Day 85 (starting from the day of first intravitreal injection to day 85)

    PART B: Tmax (Time of Maximum concentration observed)

    This is the highest concentration of drug in the blood that is measured after a dose. Cmax usually happens within a few hours after the dose is taken. The time that Cmax happens is referred to as Tmax. For some antiretroviral drugs, a high Cmax is thought to increase the risk of side effects from the drug.

  8. Part B: Cmax - Summary Statistic for PK Parameters

    Time frame: Day 1 to Day 85 (starting from the day of first intravitreal injection to day 85)

    Summary statistic for Part B of total LFG316 concentrations (pharmacokinetic analysis set) Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose

  9. Part B: Cmax_D - Summary Statistic for PK Parameters

    Time frame: Day 1 to Day 85 (starting from the day of first intravitreal injection to day 85)

    Cmax_D=ng/mL/mg

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Feb 7, 2012
Registry last updated
Jan 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.